Valneva SE, a specialty vaccine company, and Dynavax Technologies Corp., a biopharmaceutical company developing novel vaccines, have entered a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001.   Valneva separately has an agreement with the UK government to provide up to 190 million doses of VLA20011 over a five year period. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valnev...